Rakuten Investment Management Inc. Invests $20.87 Million in IQVIA Holdings Inc. $IQV

Rakuten Investment Management Inc. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 109,872 shares of the medical research company’s stock, valued at approximately $20,869,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Asset Dedication LLC grew its holdings in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in shares of IQVIA during the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp grew its holdings in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC increased its position in IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the last quarter. Finally, Root Financial Partners LLC acquired a new position in IQVIA in the 3rd quarter valued at about $43,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $233.76 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $39.81 billion, a P/E ratio of 32.07, a P/E/G ratio of 2.42 and a beta of 1.36. The stock has a 50-day moving average of $228.10 and a two-hundred day moving average of $204.62. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $195.00 to $235.00 in a research report on Thursday, October 9th. Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Mizuho set a $266.00 price objective on IQVIA in a research report on Friday, January 9th. Finally, Stifel Nicolaus upped their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $249.19.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.